RT Journal Article
SR Electronic
T1 Impact of Tumor Biological Factors on Response to Pre-operative Epirubicin and Paclitaxel Chemotherapy in Primary Breast Cancer
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 1031
OP 1038
VO 27
IS 2
A1 WARM, MATHIAS
A1 KATES, RONALD
A1 MALLMANN, PETER
A1 DICK, MICHÈLLE
A1 NAWROTH, FRANK
A1 HARBECK, NADIA
A1 PAEPKE, STEFAN
A1 THOMAS, ANKE
YR 2007
UL http://ar.iiarjournals.org/content/27/2/1031.abstract
AB Background: The objective of this study was to determine the predictive impact of several established tumor biological factors (progesterone receptor, estrogene receptor, HER2/neu, and Ki-67) on response to pre-operative combination chemotherapy with epirubicin and paclitaxel in a representative group of primary breast cancer patients. Patients and Methods: Thirty-eight primary breast cancer patients (metastasis-negative) received pre-operative chemotherapy with epirubicin and paclitaxel. The response characteristics analyzed included pathological complete response and partial remission determined by 3D ultrasound, as well as down-staging and breast conserving surgery. Results: Pathologically complete response occurred in six patients. Overexpression of HER2/neu, low (negative) hormone receptors and high Ki-67 were all significant positive predictive factors for response to pre-operative chemotherapy. Conclusion: HER2/neu overexpression is predictive for response not only to trastuzumab, but also to epirubicin and paclitaxel. Copyright© 2007 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved